Ars Pharmaceuticals Inc (SPRY) Stock Price, Quote & News

Company Profile

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Industry: Biotechnology

Sector: Healthcare

Phone: 858 771 9307

Website: ars-pharma.com

Address:

11682 El Camino Real, Suite 300, San Diego, United States

DARKP00L May. 13 at 12:04 PM

$SPRY 08:03 on May. 13 2026 ARS Pharmaceuticals Appoints Donn Casale President, Effective June 1 #tradeideas

0 · Reply

JcoalX May. 12 at 9:24 PM

$SPRY my wife wants me to buy this because she sat thru a lecture about emergency medicine. Epinephrine is one of them. Different ways of administering epinephrine during an emergency like injection from a syringe after drawing it out of a glass vial, epi pen, and now the newest is the nasal spray. It also talked about the cost of each product and their shelf life. Epi pen was the worst. It costs like $600 usd per two-pack and it only last 18 mo, whereas this spray is supposedly less with a longer shelf life. Who knows the cost in Canada. She got the fancy creds behind her name and I’m just a degenerate biotech gambler. Should I start a position???

1 · Reply

Mariorx May. 12 at 7:51 PM

$SPRY added to positon here

0 · Reply

Stone52 May. 11 at 11:58 PM

$SPRY over 550.000 shares covered the last 2 weeks in April.

0 · Reply

WaspofWallStreet May. 11 at 8:06 PM

$SPRY —$230 million in SG&A (Selling, General, and Administrative) expenses for 2025 is a massive number for a company that brought in $84 million in revenue. Yet another example of rewarding themselves early with outrageous compensation packages. Their top four already just shy of $20 million. In the CEO paying himself 8.5% of the companies total annual revenue??

1 · Reply

Sdwg May. 7 at 3:33 PM

$SPRY lol....she never disappoints does she? glta

0 · Reply

MassNortheast May. 7 at 2:55 PM

$SPRY $WOLF @ELI666 SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Friday, May 15, 2026, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its first quarter 2026 financial results and business highlights. https://ir.ars-pharma.com/news-releases/news-release-details/ars-pharmaceuticals-announces-conference-call-and-webcast-its-4/

0 · Reply

Stone52 May. 7 at 2:31 PM

$SPRY Viatris Epi Pen sales Q1 $101.1 million vs $96.7 million a year ago. +4.55% YoY

1 · Reply

Stone52 May. 7 at 1:34 PM

$SPRY Viatris epi pen sales GREW in Q1. So, either SPRY grew the overall market or Houston, we have a problem.

0 · Reply

ELI666 May. 7 at 8:34 AM

$WOLF AND $SPRY ✅ SPRY presents an extreme squeeze setup: 65% short float, 98% utilization, only 150K shares available to borrow, and a borrow rate that rose from 13% to 21% within five days. At the same time, institutions such as Millennium, Rubric, and BlackRock are accumulating, DP signals accumulation, and the float is shrinking. The upcoming catalyst is the Q1 report on May 13, alongside the expanded neffy label and 93% commercial coverage, placing SPRY within a sensitive window for a potential squeeze breakout.

1 · Reply

ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results

2026-04-15T10:11:10.000Z - 4 weeks ago

ARS Pharmaceuticals announces Health Canada approval of neffy 2 mg

Apr 15, 2026, 6:05 AM EDT - 4 weeks ago

neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

2026-04-09T11:14:32.000Z - 4 weeks ago

ARS Pharmaceuticals initiated with an Outperform at Northland

2026-04-09T11:13:02.000Z - 4 weeks ago

Northland starts disruptor ARS Pharmaceuticals with an Outperform

2026-03-27T12:16:24.000Z - 6 weeks ago

ARS Pharmaceuticals receives FDA approval to remove neffy 1 mg age requirement

Mar 27, 2026, 8:00 AM EDT - 6 weeks ago

ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label

Mar 11, 2026, 8:00 AM EDT - 2 months ago

ARS Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 8:30 AM EDT - 2 months ago

ARS Pharmaceuticals Earnings Call Transcript: Q4 2025

2026-03-09T10:05:06.000Z - 2 months ago

ARS Pharmaceuticals reports Q4 EPS (42c), consensus (44c)

Mar 9, 2026, 6:00 AM EDT - 2 months ago

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization

Feb 23, 2026, 8:00 AM EST - 2 months ago

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences

Feb 10, 2026, 8:00 AM EST - 3 months ago

ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting

2026-02-02T13:11:39.000Z - 3 months ago

ARS Pharmaceuticals announces CHMP of EMA adopted positive opinion for EURneffy

Feb 2, 2026, 8:00 AM EST - 3 months ago

EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to

2026-01-21T13:10:51.000Z - 3 months ago

ARS Pharmaceuticals announces California eligible for neffyinSchools program

Jan 21, 2026, 8:00 AM EST - 4 months ago

California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use

2026-01-09T14:40:36.000Z - 4 months ago

ARS Pharmaceuticals competitor gets FDA deficiency letter, says Raymond James

AQST

2025-12-29T13:10:25.000Z - 4 months ago

ARS Pharmaceuticals announces NMPA approval for neffy 2 mg

Dec 29, 2025, 8:00 AM EST - 4 months ago

neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)

Dec 3, 2025, 2:30 PM EST - 5 months ago

ARS Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 26, 2025, 8:00 AM EST - 6 months ago

ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference

2025-11-11T20:30:19.000Z - 6 months ago

ARS Pharmaceuticals management to meet with Oppenheimer

2025-11-11T13:50:42.000Z - 6 months ago

ARS Pharmaceuticals price target lowered to $35 from $40 at Oppenheimer

Nov 10, 2025, 8:30 AM EST - 6 months ago

ARS Pharmaceuticals Earnings Call Transcript: Q3 2025

2025-11-10T11:11:20.000Z - 6 months ago

ARS Pharmaceuticals reports Q3 EPS (52c), consensus (49c)

Nov 10, 2025, 6:00 AM EST - 6 months ago

ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)

2025-11-04T13:25:11.000Z - 6 months ago

ARS Pharmaceuticals launches ‘Get neffy on Us’

Nov 4, 2025, 8:00 AM EST - 6 months ago

ARS Pharma Launches Get neffy® on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray)

2025-11-04T12:55:28.000Z - 6 months ago

ARS Pharmaceuticals resumed with a Buy at Roth Capital

Nov 3, 2025, 2:23 PM EST - 6 months ago

UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Nov 3, 2025, 8:00 AM EST - 6 months ago

ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results

Nov 3, 2025, 7:45 AM EST - 6 months ago

ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

2025-10-08T12:05:50.000Z - 7 months ago

ARS Pharmaceuticals receives favorable decision from EPO on neffy

Oct 8, 2025, 8:00 AM EDT - 7 months ago

ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray)

Sep 29, 2025, 4:05 PM EDT - 8 months ago

ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®

2025-09-26T14:05:20.000Z - 8 months ago

Raymond James positive on ARS Pharmaceuticals after weekly data

2025-09-19T12:05:27.000Z - 8 months ago

ARS Pharmaceuticals announces neffy approved in Japan

Sep 17, 2025, 9:00 AM EDT - 8 months ago

ADARx Pharmaceuticals Appoints Industry Veteran, Laura Shawver, Ph.D., as Board Chair

Sep 8, 2025, 8:00 AM EDT - 8 months ago

Real-World Evidence Supports Clinical Effectiveness of neffy® (epinephrine nasal spray) in Patients Experiencing Anaphylaxis

Sep 3, 2025, 3:55 PM EDT - 8 months ago

ARS Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Aug 28, 2025, 8:00 AM EDT - 9 months ago

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 13, 2025, 8:30 AM EDT - 9 months ago

ARS Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 9 months ago

ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray)

Aug 4, 2025, 8:00 AM EDT - 10 months ago

ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results

Jul 18, 2025, 9:25 AM EDT - 10 months ago

EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

Jun 4, 2025, 5:30 PM EDT - 1 year ago

ARS Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Jun 3, 2025, 12:20 PM EDT - 1 year ago

ARS Pharmaceuticals Transcript: 45th Annual William Blair Growth Stock Conference

May 14, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Earnings Call Transcript: Q1 2025

May 14, 2025, 7:00 AM EDT - 1 year ago

ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)

May 7, 2025, 8:00 AM EDT - 1 year ago

ARS Pharmaceuticals' neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

May 5, 2025, 8:00 AM EDT - 1 year ago

ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results

May 2, 2025, 8:00 AM EDT - 1 year ago

ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians

Mar 20, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 20, 2025, 7:00 AM EDT - 1 year ago

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 5, 2025, 4:10 PM EST - 1 year ago

ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

Mar 3, 2025, 4:35 PM EST - 1 year ago

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences

Feb 20, 2025, 7:02 PM EST - 1 year ago

ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients

Feb 18, 2025, 8:00 AM EST - 1 year ago

ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting

Feb 12, 2025, 2:40 PM EST - 1 year ago

ARS Pharmaceuticals Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Jan 15, 2025, 10:30 AM EST - 1 year ago

ARS Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 6, 2025, 8:00 AM EST - 1 year ago

ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S

Dec 19, 2024, 5:25 PM EST - 1 year ago

ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

Dec 12, 2024, 2:32 PM EST - 1 year ago

ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia

Dec 4, 2024, 8:00 AM EST - 1 year ago

ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost

Nov 18, 2024, 2:25 PM EST - 1 year ago

ARS Pharmaceuticals Transcript: Stifel 2024 Healthcare Conference

Nov 13, 2024, 1:00 PM EST - 1 year ago

ARS Pharmaceuticals Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 13, 2024, 8:00 AM EST - 1 year ago

ARS Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 13, 2024, 6:30 AM EST - 1 year ago

ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 11, 2024, 7:00 AM EST - 1 year ago

ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States

Nov 9, 2024, 5:30 PM EST - 1 year ago

ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)

Oct 24, 2024, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

DARKP00L May. 13 at 12:04 PM

$SPRY 08:03 on May. 13 2026 ARS Pharmaceuticals Appoints Donn Casale President, Effective June 1 #tradeideas

0 · Reply

JcoalX May. 12 at 9:24 PM

1 · Reply

Mariorx May. 12 at 7:51 PM

$SPRY added to positon here

0 · Reply

Stone52 May. 11 at 11:58 PM

$SPRY over 550.000 shares covered the last 2 weeks in April.

0 · Reply

WaspofWallStreet May. 11 at 8:06 PM

1 · Reply

Sdwg May. 7 at 3:33 PM

$SPRY lol....she never disappoints does she? glta

0 · Reply

MassNortheast May. 7 at 2:55 PM

0 · Reply

Stone52 May. 7 at 2:31 PM

$SPRY Viatris Epi Pen sales Q1 $101.1 million vs $96.7 million a year ago. +4.55% YoY

1 · Reply

Stone52 May. 7 at 1:34 PM

$SPRY Viatris epi pen sales GREW in Q1. So, either SPRY grew the overall market or Houston, we have a problem.

0 · Reply

ELI666 May. 7 at 8:34 AM

1 · Reply

Stone52 May. 6 at 8:40 PM

$SPRY shorts trying not to let this current move get out if hand. Remember, someone purchased 4,000 of the May 15 7.5 strike calls = 400,000 shares. Something is brewing. Meanwhile, $AQST will report after market close next Wednesday and Barber will try to put some lipstick on the pig during the Thursday morning conference call.

0 · Reply

OracleofOntario May. 6 at 7:19 PM

$SPRY Good earnings next week will send this flying. The high short interest and 20 DTC will add substantial fuel to that fire. It's coming folks! Shorts had better get out while they can.

0 · Reply

ae1213 May. 6 at 4:03 PM

$AQST while they prepare another “most robust FDA application package ever”, $SPRY has gained 65% plus market share and keeps growing. They are already a dominant force in needle free space all over the world. Just imagine what another 9-12 months will bring to the market

1 · Reply

Stone52 May. 6 at 2:02 PM

$AQST Anticipate lousy earnings next week $SPRY shorty shorts starting to shake in their boots. Another push higher will make them re-think their position. All it takes is one large short holder to start to cover, which moves up the stock price even more. Then, the other naked shorts start to scramble - and the stock then goes parabolic.

0 · Reply

BigGainTom May. 5 at 4:42 PM

$ASTS $SPRY Both garbage companies with sky high short interest. SPRY collapse is next -- 42% short interest.

0 · Reply

BigGainTom May. 5 at 11:34 AM

$SPRY I'm going to start loaning out my 100 shares to short on Fidelity.

1 · Reply

Stone52 May. 4 at 7:30 PM

$AQST is dead money. $SPRY on a technical breakout with shorts becoming the fuel for a huge move.

1 · Reply

Stone52 May. 4 at 6:28 PM

$SPRY Chart finally looks good from a technical standpoint. Will the shorts continue to try to keep it down or will some type of forthcoming news force them to cover? We shall see!

0 · Reply

BioPM1989 May. 4 at 4:43 PM

$SPRY Why is this fading? Look at how many analysts like it?

1 · Reply

MassNortheast May. 3 at 3:44 AM

$SPRY https://x.com/massnortheast/status/2050780062786449532?s=46&t=Mk_HwNDTGlTcscWc3dtzWA

0 · Reply

briank012345 May. 1 at 9:16 AM

$SPRY let me guess, back to $7.65 today?

0 · Reply

ae1213 Apr. 30 at 8:00 PM

$SPRY let’s hear the deep analysis of today trading from the local genius below. This is the taste for you of things to come. What a dummy! $AQST today … not so much

1 · Reply

Market Cap	853.99M
Revenue (ttm)	84.28M
Net Income (ttm)	-171.30M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-203.25%
Debt to Equity Ratio	1.47

Volume	1,128,800
Avg Vol	1,603,834
Day's Range	N/A - N/A
Shares Out	99.30M
Stochastic %K	49%
Beta	0.93
Analysts	Strong Sell
Price Target	$24.25